Sign up online today & collaborate
or click here to find out more
Southampton, UK & New York, USA – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, and the Southampton Clinical Trials Unit at the University of Southampton today announced a partnership to accelerate drug development across the United Kingdom.
Southampton’s Clinical Trials Unit (SCTU), part of the UK Clinical Research Collaboration, will leverage the Medidata Clinical Cloud® to conduct more complex and scientifically rigorous clinical research. Funded by Cancer Research UK and the National Institute for Health Research (NIHR), SCTU’s portfolio consists of a diverse set of clinical development programs, including early-phase industry collaborations; multi-arm, multi-stage phase II and phase III trials; large pragmatic trials and stratified medicine program trials.
SCTU is using Medidata’s technology platform to generate high-quality, standardized data that industry partners can use to support late-stage development programs and drug approval submissions in the UK and US.
“At the Southampton Clinical Trials Unit, University of Southampton, we pride ourselves on working with the most skilled, experienced partners, investigators and sites to conduct high-quality, efficient trials. This new development could lead to more impactful clinical results that will potentially benefit the future treatment of patients in the UK and further afield,” said Professor Gareth Griffiths, director of the Southampton CTU. “With Medidata’s cutting-edge technology and off-the-shelf integration, we will be able to take on more complex and efficient studies, finding evidence of benefit in an academic research environment which could help industry by shortening their drug commercialization cycles and complementing other innovative work.”
The University is implementing Medidata’s cloud-based technology for electronic data capture, management and reporting (Medidata Rave®), clinical trial management (Medidata CTMS®) and medical coding (Medidata Coder®), enabling the SCTU to streamline clinical trials across all therapeutic areas, including oncology, respiratory, critical care and psychology. The first two studies leveraging the Medidata Clinical Cloud will focus on asthma and bladder cancer.
“Southampton’s Clinical Trials Unit is well known across the UK for its expertise in the design, conduct and analysis of complex clinical trials,” said Christian Hebenstreit, Medidata’s managing director of EMEA. “Medidata is delighted to partner with the University to drive further innovation and efficiencies across Southampton’s research portfolio, while strengthening collaborations between academia and industry. Working together, we can expedite the research, discovery and development process to deliver promising new candidates to patients sooner.”
|Company||University of Southampton|